Daniel Gottlieb, MD
Cardiovascular Disease · Burien, WANPI 1790778793
Payments from drug & device makers
Across 802 payments — averaging $75.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$20K
- Novartis$13K
- AstraZeneca$10K
- Siemens Medical Solutions USA, Inc.$4K
- Boston Scientific$2K
- Amgen$2K
- plus $9K from 28 others
Across 3 payments — averaging $14,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42K
What the payments were for
- Consulting fees$2,66012%
- Speaking & faculty fees$2,45011%
- Travel & lodging$7563%
- Food & beverage$17,00774%
- Education$1961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 91 | $19,806 |
| Novartis | 220 | $13,210 |
| AstraZeneca | 65 | $10,341 |
| Siemens Medical Solutions USA, Inc. | 4 | $4,360 |
| Boston Scientific | 41 | $2,195 |
| Amgen | 66 | $1,545 |
| Bayer | 47 | $1,426 |
| Johnson & Johnson | 51 | $1,274 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $966 |
| Edwards Lifesciences | 10 | $938 |
| Boehringer Ingelheim | 33 | $618 |
| E.r. Squibb & Sons, L.L.C. | 17 | $614 |
| Pfizer | 27 | $511 |
| Merck | 18 | $481 |
| Novo Nordisk | 8 | $379 |
| Kowa Pharmaceuticals America, Inc. | 31 | $339 |
| Lexicon Pharmaceuticals, Inc. | 8 | $279 |
| Regeneron Healthcare Solutions, Inc. | 10 | $229 |
| Impulse Dynamics (USA) Inc. | 6 | $189 |
| Esperion Therapeutics, Inc. | 12 | $176 |
| Shockwave Medical, Inc | 2 | $161 |
| CMP Pharma, Inc. | 7 | $146 |
| Kestra Medical Technology Services, Inc. | 3 | $130 |
| Abiomed | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Bardy Diagnostics, Inc. | 2 | $40 |
| Medtronic | 1 | $30 |
| Baxter Healthcare | 1 | $28 |
| GSK | 1 | $25 |
| Medicomp Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACUSON Sequoia Diagnostic Ultrasound System$1,700
- SC2000$1,640
- Watchman$1,167
- ACUSON Origin Diagnostic Ultrasound System$1,020
- LifeVest$750
- SAPIEN 3 Ultra RESILIA$457
- VERQUVO$443
- Edwards SAPIEN 3 Transcatheter Heart Valve$327
- CAMZYOS$283
- XARELTO$260
- FARXIGA$255
- Kerendia$243
- Ozempic$125
- Impella$124
- Inpefa$124
- OPTICROSS$112
- EVUSHELD$103
- AVVIGO Guidance System$102
How this compares
$60,756 in reported general payments places this provider in the 90th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 416 | $535,940 |
| JardianceEmpagliflozin | 109 | $157,091 |
| XareltoRivaroxaban | 116 | $130,791 |
| VascepaIcosapent Ethyl | 111 | $105,637 |
| Repatha SureclickEvolocumab | 83 | $84,850 |
| EntrestoSacubitril/Valsartan | 51 | $58,423 |
| BrilintaTicagrelor | 65 | $56,481 |
| Repatha SyringeEvolocumab | 20 | $19,858 |
| KerendiaFinerenone | 24 | $15,018 |
| Icosapent Ethyl | 36 | $14,757 |
| Telmisartan | 397 | $12,444 |
| Ezetimibe | 404 | $8,653 |
| Atorvastatin Calcium | 769 | $8,504 |
| Rosuvastatin Calcium | 372 | $6,137 |
| Amiodarone Hcl | 102 | $5,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $511 | $535,940416 claims |
| Boehringer IngelheimJardiance | $618 | $157,091109 claims |
| Johnson & JohnsonXarelto | $1,274 | $130,791116 claims |
| NovartisEntresto | $13,210 | $58,42351 claims |
| AstraZenecaBrilinta | $10,341 | $56,48165 claims |
| BayerKerendia | $1,426 | $15,01824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Burien
- Vinay MalhotraTacoma$5M
- Francis KimSeattle$1.7M
- Ahmad SlimTacoma$1.1M
- Kelley BranchSeattle$715K
- Robert BersinBellevue$677K
- Mariko HarperSeattle$453K
- David OwensSeattle$325K
- John PetersenSeattle$309K
- Bryan FuhsSpokane$268K
- Eugene YangBellevue$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.